The move from accuracy studies to randomized trials in pet: Current status and future directions

Journal of Nuclear Medicine

Volumn 55, Issue 8, 2014, Pages 1228-1234

  Siepe, Bettina ^a   Hoilund Carlsen, Poul Flemming ^b   Gerke, Oke ^b,c   Weber, Wolfgang A ^d   Motschall, Edith ^a   Vach, Werner ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Diagnostic randomized controlled trial; Patient important outcome; Positron emission tomography; Systematic review

Indexed keywords

ARTICLE; CANCER STAGING; CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; MOLECULAR IMAGING; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TOTAL QUALITY MANAGEMENT; TREATMENT PLANNING; PROCEDURES;

HUMANS; POSITRON-EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY;

EID: 84905434902     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.127076     Document Type: Article

References (40)

1. Schünemann HJ, Oxman AD, Brozek J, et al.; GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336:1106-1110.
2. Tunis SR, Benner J, McClellan M. Comparative effectiveness research: policy context, methods development and research infrastructure. Stat Med. 2010;29:1963-1976.
3. Fletcher JW, Djulbegovic B, Soares HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480-508.
4. Scheibler F, Raatz H, Suter K, et al. Benefit assessment of PET in malignant lymphomas: the IQWiG point of view. Nuklearmedizin. 2010;49:1-5.
5. Ferrante di Ruffano L, Hyde CJ, McCaffery KJ, Bossuyt PM, Deeks JJ. Assessing the value of diagnostic tests: a framework for designing and evaluating trials. BMJ. 2012;344:e686.
6. Medical Services Advisory Committee. Guidelines for the Assessment of Diagnostic Technologies. Canberra, Australian Capital Territory, Australia: Medical Services Advisory Committee; 2005.
7. Trikalinos TA, Siebert U, Lau J. Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. Med Decis Making. 2009;29:E22-E29.
8. Vach W, Høilund-Carlsen PF, Gerke O, Weber WA. Generating evidence for clinical benefit of PET/CT in diagnosing cancer patients. J Nucl Med. 2011;52(suppl 2):77S-85S.
9. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-smallcell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1393.
10. Scheibler F, Zumbé P, Janssen I, et al. Randomized controlled trials on PET: a systematic review of topics, design, and quality. J Nucl Med. 2012;53:1016-1025.
11. Guyatt G, Montori V, Devereaux PJ, Schünemann H, Bhandari M. Patients at the center: in our practice, and in our use of language. ACP J Club. 2004;140:A11-A12.
12. Deeks JJ. Assessing outcomes following tests. In: Price CP, Christenson EH, eds. Evidence-Based Laboratory Medicine: Principles, Practice and Outcomes. 2nd ed. Washington, DC: AACC Press; 2007:95-111.
13. Lu B, Gatsonis C. Efficiency of study designs in diagnostic randomized clinical trials. Stat Med. 2013;32:1451-1466.
14. de Bree R, van der Putten L, Hoekstra OS, et al.; RELAPS Study Group. A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy. Contemp Clin Trials. 2007;28:705-712.
15. Plewnia C, Reimold M, Najib A, Reischl G, Plontke SK, Gerloff C. Moderate therapeutic efficacy of positron emission tomography-navigated repetitive transcranial magnetic stimulation for chronic tinnitus: a randomised, controlled pilot study. J Neurol Neurosurg Psychiatry. 2007;78:152-156.
16. Mullani NA, Caras D, Ahn C, et al. Fewer women than men have positive SPECT and PET cardiac findings among patients with no history of heart disease. J Nucl Med. 2000;41:263-268.
17. Maziak DE, Darling GE, Inculet RI, et al. Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med. 2009;151:221-228.
18. Sobhani I, Tiret E, Lebtahi R, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer. 2008;98:875-880.
19. Monteil J, Vergnenègre A, Bertin F, et al. Randomized follow-up study of resected NSCLC patients: conventional versus 18F-DG coincidence imaging. Anticancer Res. 2010;30:3811-3816.
20. Herder GJ, Kramer H, Hoekstra OS, et al. Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol. 2006;24:1800-1806.
21. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002-2012.
22. Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol. 2001;37:81-88.
23. Tsai CS, Lai CH, Chang TC, et al. A prospective randomized trial to study the impact of pretreatment FDG-PET for cervical cancer patients with MRI-detected positive pelvic but negative para-aortic lymphadenopathy. Int J Radiat Oncol Biol Phys. 2010;76:477-484.
24. Viney RC, Boyer MJ, King MT, et al. Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-smallcell lung cancer. J Clin Oncol. 2004;22:2357-2362.
25. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361:32-39.
26. Ruers TJ, Wiering B, van der Sijp JR, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. J Nucl Med. 2009;50:1036-1041.
27. Djulbegovic B, Kumar A, Soares HP, et al. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute sponsored cooperative oncology groups, 1955 to 2006. Arch Intern Med. 2008;168:632-642.
28. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 1996;125:605-613.
29. Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma. 2007;48:1721-1727.
30. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305-332.
31. Buyse M, Michiels S, Sargent DJ, et al. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn. 2011;11:171-182.
32. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23:2020-2027.
33. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging: executive summary-a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2003;108:1404-1418.
34. Silvestri GA, Tanoue LT, Margolis ML, et al. The noninvasive staging of nonsmall cell lung cancer: the guidelines. Chest. 2003;123(suppl):147S-156S.
35. Silvestri GA, Gould MK, Margolis ML, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd ed.). Chest. 2007;132(suppl):178S-201S.
36. The American Thoracic Society and the European Respiratory Society. Pretreatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med. 1997;156:320-332.
37. Desch CE, Benson AB, Somerfield MR, et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2005;23:8512-8519.
38. Desch CE, Benson AB, Smith TJ, et al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol. 1999;17:1312-1321.
39. Benson AB, Desch CE, Flynn PJ, et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol. 2000;18:3586-3588.
40. Balleyguier C, Sala E, Da Cunha T, et al. Staging of uterine cervical cancer with MRI: guidelines of the European Society of Urogenital Radiology. Eur Radiol. 2011;21:1102-1110.